Founder & Chief Executive Officer
Dr. Trebley brings over 10 years experience in early stage asset development to the MBV team. Prior to MBV, he was the Head of Startups at the Indiana University Research and Technology Corporation. He was responsible for assisting Indiana University faculty, staff and students form and run more than 25 startup companies. Specifically, he assisted with university inventors to form a new entity and find initial funding through early stage resources like the SBIR/STTR programs, angel investment, corporate partners and venture capital. The program's success and popularity with top scientists and physicians inspired the formation of Monon Bioventures.
Joe also served in technology transfer at the Purdue Research Foundation managing a wide range of portfolios in the medical device, software, pharmaceutical, agriculture, and chemical disciplines. Previously, he worked as a Principle within the venture capital group In-Vivo Ventures and served as Vice President of Research and Development for Kylin Therapeutics.
Founder & Chief Financial Officer:
Jim Schulz is a serial entrepreneur with over 20 years of financial experience working with public accounting firms, Fortune 500 companies and small start-up companies. Jim graduated from Indiana University, Bloomington, in 1992 and worked for over seven years with Ernst & Young (E&Y). While working at E&Y, Jim supported a variety of clients specializing in manufacturing, financial services and transportation industries. After leaving E&Y, Jim worked for 5 years in various financial and operational roles with Eli Lilly and Company including corporate Research and Development Reporting and the Global Oncology Platform Team.
Jim left Eli Lilly to pursue more entrepreneurial opportunities and began working as the Director of Finance for Suros Surgical Systems. After Suros was acquired by Hologic Inc, for $240 million, Jim focused his role in Upward Focus to support various life science companies in the medical device and pharmaceutical industries. Since 2007, Jim has helped several clients raise over $200 million in capital and was involved in the merger of Assembly Pharmaceuticals to Ventrus Biosciences, Inc. in July of 2014 and the sale of Naurex Inc. to Allergan for $560 million in August of 2015.
Kevin Meyer has over 10 years of experience in the life sciences industry, having invented, patented, and commercialized a diverse portfolio of technologies. Most recently, Kevin helped found Perfinity Biosciences, leading the development and commercialization of tools that accelerate protein drug development and clinical research. These products are being sold by ThermoFisher Scientific and Shimadzu Scientific Instruments. Prior to Perfinity, Kevin led the development of the Accuplex technology, a test that detects heartworm antigen and the infectious agents responsible for Lyme disease, anaplasmosis, and ehrlichiosis in dogs which was acquired by Antech diagnostics. Kevin has also worked for multiple pharmaceutical companies as a formulations and organic chemist making patented formulations of Albaconazole and Ongentys. Kevin is a graduate of Wabash College with a BA in chemistry.
Jake Reder cofounded Celdara Medical and currently serves as a Director and as CEO. He had previously founded the New Ventures Office at Dartmouth Medical School and still serves as its first Director. Prior to Dartmouth, Jake led business development, open innovation, and knowledge management initiatives at Cabot Corporation where he served as a member of Cabot’s Research Council, Technology Board, and Nanotechnology EHS Council. Jake joined Cabot from PolyTechnos Venture-Partners, a Munich-based venture capital firm. He has served on numerous non- and for-profit boards, including Virtici, MBV, StemSynergy Therapeutics, NIH’s TREAT Program and the University of Vermont’s SPARK Program. Jake has testified before Congress on entrepreneurship, was appointed by the Governor to the New Hampshire Innovation Research Center’s Board of Directors, and by US Senator Jeanne Shaheen to her Small Business Advisory Council. Jake earned a B.Sc. with First Class Honours from the University of Waterloo, and a Ph.D. (Chemistry) as a Brown-Wetherill Fellow at Purdue University and Ludwig Maximilians Universität.
Neil Fanger has over 15 years experience in the life sciences industry, spanning business development, product strategy, and biological research. In 2002, Dr. Fanger co-founded Teranode Corporation (acquired by Rage Frameworks in 2010). At Teranode, he led teams that introduced new products into the marketplace and secured worldwide partnerships with strategic customers such as Pfizer, AstraZeneca, Boehringer Ingelheim, and GlaxoSmithKline. Prior to Teranode, Dr. Fanger focused on product development at Corixa and Immunex. Dr. Fanger is co-inventor on several patents covering novel biological therapeutics and software technologies, and co-author on numerous research publications in leading scientific journals. He earned a PhD in physiology from Dartmouth Medical School, and a BS in chemistry from Denison University.
Michael Fanger is currently Founder, Chairman, and CSO of Celdara Medical, LLC. Previously, Dr. Fanger was co-founder, President and Chief Executive Officer of Celldex Therapeutics Inc. (NASDAQ: CLDX), as well as the co-founder and Director of Medarex, Inc. (previously NASDAQ: MEDX, acquired by BMS in 2009) from its inception in 1987 until 2004. Dr. Fanger has been a Professor of Microbiology and Immunology and Medicine at Dartmouth Medical School since 1981, and was a Chairman of the Department of Microbiology and Immunology from 1992 until 2002. Dr. Fanger is co-inventor on 91 patents covering novel biological therapeutics and software technologies, and co-author on 160 research publications in leading scientific journals. He is a graduate of Wabash College with a BS in Chemistry and received his PhD in Biochemistry from Yale University.
Jaswant S. Gidda, Ph. D. has extensive drug discovery and development experience in big pharma (Eli Lilly & Co) and as an entrepreneur in biotechnology industry. He is currently President, Chief Executive Officer and Director of Anagin, Inc and previously was part of the original team of Marcadia Biotech and Calibrium LLC and served as Vice President of Research and Development. He joined Naurex, Inc. as VP of RD before joining Assembly Biosciences as a Consultant. Both Marcadia and Naurex had successful exits (former acquired by Roche and the later by Allergan). Jaswant is co-discoverer and developer of two market drugs (Axid® and Enterg ® ) and has led more than 20 program or project teams through Phase 1 and II. Jas has sixteen US issued patents (use and composition of matter)
Jaswant received his Master of Honors and Ph. D. from Panjab University, India and his post- doctoral training in neuropharmacology at University of Texas Southwestern Medical School.
Over the years he has acquired experience in Neuroscience, endocrinology and Gastroenterology. Jas taught at University of Texas and Harvard medical school and has numerous publications in prestigious journals such as PNAS, J. Pharmacol. Exp. Ther., Journal of neurophysiology, American Journal of physiology, Gastroenterology and Nature Chemical Biology
Mark L. Heiman, Ph.D. has 20+ years at Eli Lilly & Co where he served as researcher and CSO of obesity drug discovery. He is currently CSO and Vice President of MicroBiome Therapeutics. Mark is a Fellow of the Obesity Society and serves on the SAB of Helmholtz Alliance for Imaging and Curing Environmental Metabolic Diseases (ICEMED) in Munich, Germany. He serves on the editorial boards of Molecular Metabolism and J of Hepatology & Gastroenterology.
Dr. Heiman received his Ph.D. in Physiology from Louisiana State University School of Medicine. His postdoctoral training in neuroendocrinology was at the Indiana University School of Medicine. He joined the faculty of Medicine at Tulane University where he co-discovered the drug Lanreotide before joining Lilly. Mark has authored over 100 scientific papers and is best known for his seminal work performed at Lilly, which defined the key roles for both leptin and ghrelin in regulating energy balance.
Graeme Martin. Ph.D is a pharmaceutical industry veteran with an extensive track record in multinational Pharmaceutical R&D, and external venture creation and management. Specific interest in formulation, foundational management and strategic guidance of early stage therapeutic life science companies, as well as participating as a NED in more mature, private biotech companies. Graeme has over thirty years of experience including roles at Glaxo Wellcome, Roche and for the previous 14 years served as President and CEO of Takeda Ventures, Inc.